Corpus Intelligence IC Memo — WEST VIRGINIA UNIVERSITY HOSPITALS 2026-04-26 05:01 UTC
IC Memo — WEST VIRGINIA UNIVERSITY HOSPITALS
Investment Committee Memorandum | WV | 704 beds | Grade B | EBITDA uplift $114.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WEST VIRGINIA UNIVERSITY HOSPITALS

CCN 510001 | MONONGALIA, WV | 704 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

WEST VIRGINIA UNIVERSITY HOSPITALS is a 704-bed large academic medical center in MONONGALIA, WV with $1.55B in net patient revenue and a -12.2% operating margin. The hospital serves a payer mix of 23.8% Medicare, 7.7% Medicaid, and 68.5% commercial.

Thesis: Undervalued. Our ML models identify $114.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -12.2% to -4.8% (+736bps).

Net Revenue HCRIS$1.55B
Current EBITDA COMPUTED$-189.4M
Operating Margin COMPUTED-12.2%
Occupancy HCRIS81.5%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS34.5%
Distress Probability ML42.6%

2. Market Context & Competitive Position

62
WV Hospitals
-0.3%
State Median Margin
535
Comparable Hospitals

WV has 62 Medicare-certified hospitals with a median operating margin of -0.3%. The target's margin of -12.2% places it below the state median. Among 535 size-comparable peers (352-1408 beds), the median margin is -4.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (352-1408), prioritizing same-state peers. 535 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WEST VIRGINIA UNIVERSITY HOSPI (Target)WV704$1.55B-12.2%
ST. LUKES HOSPITALPA633$8.94B87.9%
STANFORD HEALTH CARECA657$6.76B3.7%
CLEVELAND CLINIC HOSPITALOH1326$6.38B-17.7%
VANDERBILT UNIVERSITY MEDICAL TN1084$5.44B-15.9%
UCSF MEDICAL CENTERCA834$5.44B-5.4%
UT MD ANDERSON CANCER CENTERTX721$4.90B-0.8%
UNIV OF MI HOSPITALS & HLTH CTMI951$4.62B-1.4%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $114.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$32.6M+210bp18mo
Cost to Collect4.5%2.5%$31.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$30.8M+198bp12mo
A/R Days Reduction5200.0%3800.0%$18.9M+122bp9mo
Clean Claim Rate88.0%96.0%$994K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$32.6M
Cost to Collect
$31.1M
Denial Rate Reduction
$30.8M
A/R Days Reduction
$18.9M
Clean Claim Rate
$994K
Total EBITDA Uplift$114.4M
Current EBITDA$-189.4M
+ RCM Uplift+$114.4M
Pro Forma EBITDA$-75.0M
Current Margin-12.2%
Pro Forma Margin-4.8%
WC Released (1x)$59.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-291.3M$-105.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-291.3M$-210.8M0.00x-100.0%
Bull Case9.0x11.0x$-262.2M$72.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-262.2M$1.1M0.00x-100.0%
Bear Case11.0x10.0x$-320.5M$-582.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-320.5M$-745.1M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 535 hospitals with 352-1408 beds
  • Same-state prioritization (n=2)
  • Comp margins: P25=-14.8% / P50=-4.7% / P75=4.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.